Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

China Prepares To Send Food And Drug Safety Officials To The U.S.

This article was originally published in PharmAsia News

Executive Summary

WASHINGTON, DC & SHANGHAI - Shortly after U.S. FDA established offices in Beijing, Shanghai and Guangzhou, China last week, China announced that it will also open offices in the U.S

You may also be interested in...



China Beefs Up Regs For Drugs Containing Codeine, Online Distributors: SFDA Press Conference

SHANGHAI - China's State FDA will revoke the business licenses of companies that sell and distribute oral solutions containing codeine - a common painkiller and cough suppressant - without a doctor's prescription, SFDA said at its monthly press conference in Beijing, Dec. 8

China Beefs Up Regs For Drugs Containing Codeine, Online Distributors: SFDA Press Conference

SHANGHAI - China's State FDA will revoke the business licenses of companies that sell and distribute oral solutions containing codeine - a common painkiller and cough suppressant - without a doctor's prescription, SFDA said at its monthly press conference in Beijing, Dec. 8

U.S. FDA Launches First Overseas Office in Beijing

U.S. HHS Secretary Michael Leavitt and U.S. FDA Commissioner Andrew von Eschenbach officially opened the first overseas FDA office Nov. 19 in Beijing in a continuing effort to improve foreign product safety, while the agency faces criticism from the U.S. Congress

Latest Headlines
See All
UsernamePublicRestriction

Register

SC067231

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel